Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
NCT07544654 Etoposide Advanced Neuroendocrine Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07544654 Etoposide Advanced Neuroendocrine Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07544654 clinical trial report covering Etoposide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07549386 Diacerein Pain Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07549386 Diacerein Pain Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07549386 clinical trial report covering Diacerein, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07551544 Bacillus Calmette-Guerin(ImmunityBio) Non-Muscle Invasive Bladder Neoplasms Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07551544 Bacillus Calmette-Guerin(ImmunityBio) Non-Muscle Invasive Bladder Neoplasms Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07551544 clinical trial report covering Bacillus Calmette-Guerin(ImmunityBio), Phase 3, endpoints, sponsor, geography, readout timing and development wh
Read →
ChiCTR2600124664 Obefazimod Colitis, Ulcerative Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
ChiCTR2600124664 Obefazimod Colitis, Ulcerative Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
ChiCTR2600124664 clinical trial report covering Obefazimod, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
ChiCTR2600125501 Ticagrelor Cerebrovascular Disorders Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
ChiCTR2600125501 Ticagrelor Cerebrovascular Disorders Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
ChiCTR2600125501 clinical trial report covering Ticagrelor, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07564726 Amlodipine Besylate Primary hypercholesterolemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07564726 Amlodipine Besylate Primary hypercholesterolemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07564726 clinical trial report covering Amlodipine Besylate, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07593924 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine(Sinovac Life Sciences) Pneumococcal Infections Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07593924 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine(Sinovac Life Sciences) Pneumococcal Infections Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07593924 clinical trial report covering 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine(Sinovac Life Sciences), Phase 3, endpoints, sponsor, geo
Read →
NCT07563634 Brivaracetam Epilepsies, Partial Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07563634 Brivaracetam Epilepsies, Partial Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07563634 clinical trial report covering Brivaracetam, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
CRLF1 Biologics Sequence Review Report 2026: Cytokine receptor-like factor 1 Similarity and Patent-Risk Signals
8 min read
CRLF1 Biologics Sequence Review Report 2026: Cytokine receptor-like factor 1 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CRLF1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
C1QTNF9B Biologics Sequence Review Report 2026: Complement C1q and tumor necrosis factor-related protein 9B Similarity and Patent-Risk Signals
8 min read
C1QTNF9B Biologics Sequence Review Report 2026: Complement C1q and tumor necrosis factor-related protein 9B Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of C1QTNF9B protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CR1L Biologics Sequence Review Report 2026: Complement component receptor 1-like protein Similarity and Patent-Risk Signals
8 min read
CR1L Biologics Sequence Review Report 2026: Complement component receptor 1-like protein Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CR1L protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
C1QTNF7 Biologics Sequence Review Report 2026: Complement C1q tumor necrosis factor-related protein 7 Similarity and Patent-Risk Signals
8 min read
C1QTNF7 Biologics Sequence Review Report 2026: Complement C1q tumor necrosis factor-related protein 7 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of C1QTNF7 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →